Edgewise Therapeutics, Inc. (EWTX) intrinsic value & 10-year financials
Edgewise Therapeutics, Inc. (EWTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $37.19
- Market cap
- $3.8B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -20.2%
- Free cash flow (FY2025)
- -$144.1M
EWTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$167.8M | -$1.63 | -$144.1M | — | -43.2% |
| FY2024 | — | -$133.8M | -$1.45 | -$110.3M | — | -48.2% |
| FY2023 | — | -$100.2M | -$1.57 | -$97.7M | — | -40.4% |
| FY2022 | — | -$67.6M | -$1.26 | -$58.2M | — | -21.8% |
| FY2021 | — | -$42.8M | -$1.14 | -$34.2M | — | -35.9% |
| FY2020 | — | -$17.1M | -$0.45 | -$14.8M | — | 68.1% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Edgewise Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Edgewise Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -38.4% ROIC.
Edgewise Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Edgewise Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.